Advertisement

Addition of Ivosidenib to Azacitidine in Newly Diagnosed IDH1-Mutated AML
Posted: 05/16/2022 | By: Matthew Stenger

Question 1 of 5

The hazard ratio for progression-free survival for the ivosidenib/azacitidine group vs the placebo/azacitidine group was:

Choose 1

A
0.33
B
0.46
C
0.69
D
0.03

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage